STIOLTO RESPIMAT

Peak

tiotropium bromide and olodaterol

Boehringer Ingelheim

NDAINHALATIONSPRAY, METERED

Approved

May 2015

Lifecycle

Peak

Competitive Pressure

8/100

Data completeness

3/8 — Basic

Drug data last refreshed Yesterday · AI intelligence enriched 3w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

STIOLTO RESPIMAT is a fixed-dose combination inhaler containing tiotropium bromide (a long-acting muscarinic antagonist) and olodaterol (a long-acting beta-2 agonist) delivered via metered spray. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD), targeting airway obstruction through dual bronchodilator mechanisms. The combination provides 24-hour symptom control and is positioned as a once-daily maintenance therapy for COPD patients requiring multiple bronchodilators.

$0.4BPart D

4.4 years to LOE

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Why This Matters for Your Career

LOE in ~5 years — strategic planning for patent cliff underway

Worked on STIOLTO RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Career Relevance

STIOLTO RESPIMAT, as a peak-stage respiratory combination product, supports brand management, respiratory field sales, and pulmonary medical science liaison roles focused on COPD patient management and formulary access. Critical skills include COPD pathophysiology, inhaler technique training, managed care negotiations, and patient-focused outcomes communication. Currently, zero linked job openings are reported, reflecting the mature lifecycle stage and stable market position requiring maintenance-level commercial infrastructure rather than launch-phase expansion.